Transformative Neuroscience News Today

-- Observed reductions of 11% and 12% in 24- and 27-hydroxycholesterol in cerebrospinal fluid , respectively, indicating potential improvement of cholesterol metabolism in the brain -- -- Observed 8%...

Phase 2a data published in The Lancet’s eBioMedicinesupports further development of UB-311

Toronto, ON (PRWEB) June 20, 2023 -- The Global Alzheimers Platform Foundation (GAP) is delighted to announce a collaborative, free webinar focusing on the

Broad participation at this year's congress highlights Prothena's leadership in advancing next generation treatments for Alzheimer's and Parkinson's disease Oral presentation on PRX012, Prothena's

Predicting when new drugs come to market in the United States has never been an exact science, but several drugs that could be approved in 2023 could have a significant impact on health for millions of people.

/PRNewswire/ -- Wren Therapeutics announced today a number of new members to its Scientific Advisory Board. Joining existing members—Tuomas Knowles, PhD; Sara...

A collection of news stories highlighting research wins, expert insights, and academic achievement.

Drugmakers Biogen and Eisai say their experimental drug lecanemab slowed the progress of Alzheimer’s disease in a large human study the companies did. The results could mean a rare victory in a field filled with failed experiments to find an effective treatment for the disease.

By Deena Beasley, Julie Steenhuysen and Rocky Swift (Reuters) - An experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and

Eisai Co Ltd and Biogen Inc on Tuesday (Sept 27) said their experimental Alzheimer's drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, marking a rare win in a field littered with failed drugs. The drug, lecanemab, slowed progress of the brain-wasting disease by 27 per cent compared with...